| Market revenue in 2025 | USD 19.1 million |
| Market revenue in 2033 | USD 36.4 million |
| Growth rate | 8.4% (CAGR from 2026 to 2033) |
| Largest segment | Episomal reprogramming |
| Fastest growing segment | MRNA Reprogramming |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming |
| Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies |
Increasing research by major players and institutions in cell programming in France is expected to boost market growth during the forecast period. For instance, in February 2020, Paul-Ehrlich-Institut announced that its scientists from France, in collaboration with Germany, successfully produced iPSCs from a healthy individual, a patient with Aicardi-Goutières syndrome, and another with Ren penning syndrome.
These proteins are implicated in both disorders and play a crucial role in the immune recognition of HIV. Using iPSCs and their derived cell types offers a pathway to acquire fresh perspectives on these syndromes and enhances understanding of the human immune system in combating HIV.
Publish Date: Jun 11, 2026
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Bio-Techne Corp | View profile | 3,050 | 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 | www.bio-techne.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
| ReproCELL | View profile | 51-100 | Yokohama, Kanagawa, Japan, Asia | reprocell.com |
| STEMCELL Technologies | View profile | 501-1000 | Vancouver, British Columbia, Canada, North America | www.stemcell.com |
| Allele Biotech | View profile | 11-50 | San Diego, California, United States, North America | www.allelebiotech.com/ |
| Alstem | View profile | 11-50 | Richmond, Virginia, United States, North America | www.alstembio.com/web/ |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell Reprogramming Market Outlook will help companies and investors design strategic landscapes.
Episomal Reprogramming was the largest segment with a revenue share of 34.55% in 2025.
Horizon Databook has segmented the France cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2021 to 2033.
Increasing research by major players and institutions in cell programming in France is expected to boost market growth during the forecast period. For instance, in February 2020, Paul-Ehrlich-Institut announced that its scientists from France, in collaboration with Germany, successfully produced iPSCs from a healthy individual, a patient with Aicardi-Goutières syndrome, and another with Ren penning syndrome.
These proteins are implicated in both disorders and play a crucial role in the immune recognition of HIV. Using iPSCs and their derived cell types offers a pathway to acquire fresh perspectives on these syndromes and enhances understanding of the human immune system in combating HIV.
Horizon Databook provides a detailed overview of country-level data and insights on the France Cell Reprogramming Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into France Cell Reprogramming Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
